The article highlights GSK's strategy of pursuing both partnerships and acquisitions to expand its pipeline in various disease areas. This approach allows GSK to leverage the expertise and assets of other companies while mitigating risks by not fully committing to a single project. However, it also raises questions about GSK's long-term commitment to these partnerships and how it will manage potential conflicts of interest. Furthermore, the article touches on the broader trend in the pharmaceuti...